Suzhou – October 7, 2026 -- Suzhou Ribo Life Science (06938.HK) and its Swedish subsidiary Ribocure Pharmaceuticals AB have submitted a Phase I Clinical Trial Application in the European Union for RBD3133, a small interfering RNA (siRNA) therapeutic targeting the INHBE gene for overweight and obesity.